Correvio Pharma Corp, A Specialty Pharmaceutical Company Focused On Commercializing Hospital Drugs, Announced That The Us Food And Drug Administration (Fda) Has Accepted For Review The Resubmitted New Drug Application (Nda) For Brinavess (Vernakalant Hydrochloride, Iv), An Antiarrhythmic Drug For The Rapid Conversion Of Recent Onset Atrial Fibrillation (Af) To Sinus Rhythm In Adult Patients. The Fda Assigned A Target Action Date Of December 24, 2019 Under The Prescription Drug User-Fee Act (Pdufa). In Its Acceptance Letter, The Fda Stated That It Is Currently Planning To Hold An Advisory Committee Meeting To Discuss This Application.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!